|
1
|
Finkel K, Perazella MA and Cohen E: Acute
kidney injury-Incidence, Pathogenesis and Outcomes. In:
Onco-Nephrology. 1st edition. Elsevier, Amsterdam, pp270-274,
2019.
|
|
2
|
Bratu OG, Cherciu AI, Bumbu A, Lupu S,
Marcu DR, Ionita-Radu F, Manea M, Furau C, Diaconu CC and Mischianu
DL: Retroperitoneal tumours-treatment and prognosis of tumour
recurrence. Rev Chim. 70:190–194. 2019.
|
|
3
|
Marcu DR, Ionita-Radu F, Iorga LD, Manea
M, Socea B, Scarneciu I, Isvoranu G, Costache R, Diaconu CC and
Bratu OG: Vascular involvement in primary retroperitoneal tumors.
Rev Chim. 70:445–448. 2019.
|
|
4
|
Draghici T, Negreanu L, Bratu OG, Stoian
AP, Socea B, Neagu TP, Stanescu AM, Manuc D and Diaconu CC:
Paraneoplastic syndromes in digestive tumors: A review. Rom
Biotechnol Lett. 24:813–819. 2019.
|
|
5
|
Perazella MA: Renal vulnerability to drug
toxicity. Clin J Am Soc Nephrol. 4:1275–1283. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kidney Disease: Improving Global Outcomes
(KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for
Acute Kidney Injury. Kidney Int Suppl. 1:1–138. 2012.
|
|
7
|
Christiansen CF, Johansen MB, Langeberg
WJ, Fryzek JP and Sørensen HT: Incidence of acute kidney injury in
cancer patients: A Danish population-based cohort study. Eur J
Intern Med. 22:399–406. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
International Agency for Research on
Cancer: Europe-Global cancer Observatory. Globoscan 2018.
https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf.
Accessed October 28, 2020.
|
|
9
|
Bratu OG, Diaconu CC, Mischianu DLD,
Constantin T, Stanescu AM, Bungau SG, Ionita-Radu F and Marcu RD:
Therapeutic options in patients with biochemical recurrence after
radical prostatectomy. Exp Ther Med. 18:5021–5025. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bratu O, Spînu D, Oprea I, Popescu R,
Marcu D, Farcaș C, Dinu M and Mischianu D: Complications of radical
retropubicprostatectomy-our experience. Romanian J Military Med.
118:23–25. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Marcu D, Spinu D, Mischianu D, Socea B,
Oprea I and Bratu OG: Oncological follow-up after radical
prostatectomy. Romanian J Military Med. 120:39–42. 2017.
|
|
12
|
Tataru AL, Furau G, Afilon J, Ionescu C,
Dimitriu M, Bratu OG, Tit DM, Bungau A and Furau C: The situation
of cervical cancers in the context of female genital cancer
clustering and burden of disease in Arad County. Romania J Clin
Med. 8(96)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lameire N, Van Biesen W and Vanholder R:
Acute renal failure. Lancet. 365:417–430. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Finkel KW and Kala J: Renal replacement
therapy in critically Ill cancer patients. In: Oncologic Critical
Care. Nates J and Price K (eds). Springer, Cham, pp1-12, 2019.
|
|
15
|
Daugirdas JT: Physiologic principles and
urea kinetic modeling. In: Handbook of Dialysis. 5th edition.
Daugirdas JT, Blake PG and Ing TS (eds). Wolters Kluwer,
Philadelphia, pp34-65, 2015.
|
|
16
|
Fathima N, Kashif T, Janapala RN, Jayaraj
JS and Qaseem A: Single-best choice between intermittent vs.
continuous renal replacement therapy: A review. Cureus.
11(e5558)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
PIRRT may help you improve resource
utilization, patient care, early patient mobilization programs.
https://www.nxstage.com/hcp/therapies/pirrt/. Accessed
September 14, 2020.
|
|
18
|
Sherman RA, Daugirdas JT and Ing TS:
Complications during hemodialysis. In: Handbook of Dialysis. 5th
edition. Daugirdas JT, Blake PG and Ing TS (eds). Wolters Kluwer,
Philadelphia, pp215-236, 2015.
|
|
19
|
Trinh-Trang-Tan MM, Cartron JP and Bankir
L: Molecular basis for the dialysis disequilibrium syndrome:
Altered aquaporin and urea transporter expression in the brain.
Nephrol Dial Transplant. 20:1984–1988. 2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mistry K: Dialysis disequilibrium syndrome
prevention and management. Int J Nephrol Renovasc Dis. 12:69–77.
2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Finkel KW and Waguespack DR: Renal
replacemet therapies. In: Onco-Nephrology. 1st edition. Finkel K,
Perazella MA and Cohen E (eds). Elsevier, Amsterdam, pp290-298,
2019.
|
|
22
|
Fliser T and Kielstein JT: Technology
insight: Treatment of renal failure in the intensive care unit with
extended dialysis. Nat Clin Pract Nephrol. 2:32–39. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Berbece AN and Richardson RMA: Sustained
low-efficiency dialysis in the ICU: Cost, anticoagulation, and
solute removal. Kidney Int. 70:963–968. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Baldwin I, Naka T, Koch B, Fealy N and
Bellomo R: A pilot randomized controlled comparison of continuous
venovenous hemofiltration and extended daily dialysis with
filtration: Effect on small solutes and acid-base balance.
Intensive Care Med. 33:830–835. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kielstein JT, Kretschmer U, Ernst T, Hafer
C, Bahr MJ, Haller H and Fliser D: Efficacy and cardiovascular
tolerability of extended dialysis in critically ill patients: A
randomized controlled study. Am J Kidney Dis. 43:342–349.
2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Schwenger V, Weigand MA, Hoffmann O, Dikow
R, Kihm LP, Seckinger J, Miftari N, Schaier M, Hofer S, Haar C, et
al: Sustained low efficiency dialysis using a single-pass batch
system in acute kidney injury-a randomized interventional trial:
The REnal replacement therapy study in intensive care unit
patiEnts. Crit Care. 16(R140)2012.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Cullis B, Abdelraheem M, Abrahams G, Balbi
A, Cruz DN, Frishberg Y, Koch V, McCulloch M, Numanoglu A, Nourse
P, et al: Peritoneal dialysis for acute kidney injury. Perit Dial
Int. 34:494–517. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Schiffl H, Lang SM and Fischer R: Daily
hemodialysis and the outcome of acute renal failure. N Engl J Med.
346:305–310. 2002.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ronco C, Bellomo R, Homel P, Brendolan A,
Dan M, Piccinni P and La Greca G: Effects of different doses in
continuous veno-venous haemofiltration on outcomes of acute renal
failure: A prospective randomised trial. Lancet. 356:26–30.
2000.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Uchino S: The epidemiology of acute renal
failure in the world. Curr Opin Crit Care. 12:538–543.
2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kellum JA, Angus DC, Johnson JP, Leblanc
M, Griffin M, Ramakrishnan N and Linde-Zwirble WT: Continuous
versus intermittent renal replacement therapy: A meta-analysis.
Intensive Care Med. 28:29–37. 2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tonelli M, Manns B and Feller-Kopman D:
Acute renal failure in the intensive care unit: A systematic review
of the impact of dialytic modality on mortality and renal recovery.
Am J Kidney Dis. 40:875–885. 2002.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sandy D, Moreno L, Lee J and Paganini EP:
A randomized stratified, dose equivalent comparison of continuous
veno-venous hemodialysis (CVVHD) vs intermittent hemodialysis (IHD)
support in ICU acute renal failure patients (ARF). J Am Soc
Nephrol. 9(225A)1998.
|
|
34
|
John S, Griesbach D, Baumgartel M,
Weihprecht H, Schmieder RE and Geiger H: Effects of continuous
haemofiltration vs intermittent haemodialysis on systemic
haemodynamics and splanchnic regional perfusion in septic shock
patients: A prospective, randomized clinical trial. Nephrol Dial
Transplant. 16:320–327. 2001.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Mehta RL, McDonald BR, Gabbai FB, Pahl M,
Pascual MT, Farkas A and Kaplan RM: Collaborative Group for
Treatment of ARF in the ICU. A randomized clinical trial of
continuous vs intermittent dialysis for acute renal failure. Kidney
Int. 60:1154–1163. 2001.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Uehlinger DE, Jakob SM, Eichelberger M, et
al: A randomized, controlled single center study for the comparison
of continuous renal replacement therapy with intermittent
hemodialysis in critically ill patients with acute renal failure. J
Am Soc Nephrol. 12(278A)2001.
|
|
37
|
Leaf DE and Waika SS: IDEAL-ICU in
context. Clin J Am Soc Nephrol. 14:1264–1267. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zarbock A, Kellum JA, Schmidt C, Van Aken
H, Wempe C, Pavenstädt H, Boanta A, Gerß J and Meersch M: Effect of
early vs delayed initiation of renal replacement therapy on
mortality in critically ill patients with acute kidney injury: The
ELAIN randomized clinical trial. JAMA. 315:2190–2199.
2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gaudry S, Hajage D, Schortgen F,
Martin-Lefevre L, Pons B, Boulet E, Boyer A, Chevrel G, Lerolle N,
Carpentier D, et al: for the AKIKI study group: initiation
strategies for renal-replacement therapy in the intensive care
unit. N Eng J Med. 375:122–133. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Teo BW, Messer JS, Chua HR, How P and
Demirjian S: Continuous Renal Replacement Therapies. In: Handbook
of Dialysis. 5th edition. Daugirdas JT, Blake PG and Ing TS (eds).
Wolters Kluwer, Philadelphia, pp268-304, 2015.
|
|
41
|
Rastegar M, Kitchlu A and Shirali AC:
Tumor lysis syndrome. In: Onco-Nephrology. 1st edition. Daugirdas
JT, Blake PG and Ing TS (eds). Elsevier, Amsterdam, pp275-280,
2019.
|
|
42
|
Kiprov DD, Sanchez A and Pusey C:
Therapeutic apheresis. In: Handbook of Dialysis. 5th edition.
Daugirdas JT, Blake PG and Ing TS (eds). Wolters Kluwer,
Philadelphia, pp333-359, 2015.
|
|
43
|
Favà A, Fulladosa X, Montero N, Draibe J,
Torras J, Gomà M and Cruzado JM: Treatment of multiple myeloma with
renal involvment: the nephrologist's view. CKD. 11:777–785.
2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hutchison CA, Cockwell P, Stringer S,
Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S,
Rajkumar SV, et al: Early reduction of serum-free light chains
associates with renal recovery in myeloma kidney. J Am Soc Nephrol.
22:1129–1136. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Clark WF, Stewart AK, Rock GA, Sternbach
M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX and Churchill DN:
Canadian Apheresis Group. Plasma exchange when myeloma presents as
acute renal failure: A randomized, controlled trial. Ann Intern
Med. 143:777–784. 2005.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Gondouin B and Hutchison CA: High cut-off
dialysis membranes: Current uses and future potential. Adv Chronic
Kidney Dis. 18:180–187. 2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hutchison CA, Heyne N, Airia P, Schindler
R, Zickler D, Cook M, Cockwell P and Grima D: Immunoglobulin free
light chain levels and recovery from myeloma kidney on treatment
with chemotherapy and high cut-off haemodialysis. Nephrol Dial
Transplant. 27:3823–3828. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Finkel K and Fabbrini P: Paolo fabbrini.
High cut-off hemodialysis for myeloma cast nephropathy-do we
finally have an answer? J Onco-Nephrol. 1:67–70. 2017.
|
|
49
|
Hutchison CA, Cook M, Heyne N, Weisel K,
Billingham L, Bradwell A and Cockwell P: European trial of free
light chain removal by extended haemodialysis in cast nephropathy
(EuLITE): A randomised control trial. Trials. 9(55)2008.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Bridoux F, Carron PL, Pegourie B,
Alamartine E, Augeul-Meunier K, Karras A, Joly B, Peraldi MN,
Arnulf B, Vigneau C, et al: Effect of high-cutoff hemodialysis vs
conventional hemodialysis on hemodialysis independence among
patients with myeloma cast nephropathy: A randomized clinical
trial. JAMA. 318:2099–2110. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Vallée AG, Chenine L, Leray-Moragues H,
Patrier L, Cognot C, Cartron G, Cristol JP and Canaud B: Online
high-efficiency haemodiafiltration achieves higher serum free light
chain removal than high-flux haemodialysis in multiple myeloma
patients: Preliminary quantitative study. Nephrol Dial Transplant.
26:3627–3633. 2011.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kirsch AH, Lyko R, Nilsson LG, Beck W,
Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR and
Krieter DH: . Performance of hemodialysis with novel medium cut-off
dialyzers. Nephrol Dial Transplant. 1:165–172. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Zweigart C, Boschetti-de-Fierro A, Hulko
M, Nilsson LG, Beck W, Storr M and Krause B: Medium cut-off
membranes-closer to the natural kidney removal function. Int J
Artif Organs. 40:328–334. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Krishnasamy R, Hawley CM, Jardine MJ,
Roberts MA, Cho YJ, Wong MG, Heath A, Nelson CL, Sen A, Mount PF,
et al: Design and methods of the REMOVAL-HD study: A tRial
evaluating Mid cut-Off value membrane clearance of albumin and
light chains in haemoDialysis patients. BMC Nephrol.
19(89)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Ronco C, Marchionna N, Brendolan A, Neri
M, Lorenzin A and Rueda AJ: Expanded haemodialysis: Expanded
haemodialysis: From operational mechanism to clinical results.
Nephrol Dial Transplant. 33 (Suppl 3):iii41–iii47. 2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Pérez-García R and Alcázar R: The dialyser
in the year 2017: Much more than a membrane. Nefrologia. 38:4–7.
2018.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
